Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Tulane to initiate XM-ONE clinical trial in kidney transplantation

Tulane University Hospital, New Orleans, LA, USA will in May start a prospective trial in Kidney Transplantation investigating the potential of cross match XM-ONE as part of the risk assessment of their patients.

28 May 2012

Positive results from Sanofi and Regeneron’s SAR236553/REGN727 Phase 2 trial on heFH

Sanofi and Regeneron Pharmaceuticals, Inc. today announced additional positive results from a Phase 2 trial of SAR236553/REGN727 in patients with heterozygous familial hypercholesterolemia (heFH).

28 May 2012

Ultra-sensitive test can diagnose diseases in their earliest stages

Scientists have developed an ultra-sensitive test that should enable them to detect signs of a disease in its earliest stages, in research published today in the journal Nature Materials.

28 May 2012

Preliminary results from Celldex’s CDX-011 Phase 2b breast cancer study

Celldex Therapeutics, Inc. today announced preliminary results from the Company's randomized Phase 2b EMERGE study of CDX-011 (glembatumumab vedotin) antibody drug conjugate in patients with glycoprotein NMB (GPNMB) expressing, advanced, heavily pretreated breast cancer. Preliminary results suggest that CDX-011 induces impressive response rates compared to current, available therapies in patients with advanced, refractory breast cancers with high GPNMB expression.

24 May 2012

Health Canada accepts Seattle Genetics’ ADCETRIS NDS for review

Seattle Genetics, Inc. announced today that the validation period is complete and Health Canada has accepted for review its New Drug Submission (NDS) for the use of ADCETRIS (brentuximab vedotin) in relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma.

24 May 2012

New liquid urine control available from Randox

The new Randox Acusera liquid urine control is designed to be both easy and convenient for laboratory staff to use. The inclusion of fully assayed target values for 18 commonly performed urine chemistry tests including Microalbumin and hCG enables consolidation and ultimately cost savings.

From Randox Laboratories Ltd. 23 May 2012

AVEO commences AV-203 Phase 1 study in advanced solid tumors

AVEO Oncology today announced the initiation of a Phase 1 study examining the safety and preliminary efficacy of AV-203 along with exploratory biomarkers in patients with advanced solid tumors.

23 May 2012

Astrocytes appear to retaliate against AD

When brain cells start oozing too much of the amyloid protein that is the hallmark of Alzheimer's disease, the astrocytes that normally nourish and protect them deliver a suicide package instead, researchers report.

23 May 2012

Panel of HuCAL Anti-Drug Antibodies to be launched by AbD Serotec

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its division for research and diagnostic antibodies, AbD Serotec, will launch a series of novel anti-drug antibodies (ADAs) to strengthen its position as a leading provider of diagnostic reagents.

23 May 2012

Mimotopes can help develop new diagnostic tests for sleeping sickness

Each year many thousands of Africans contract sleeping sickness. The cause is a unicellular parasite, a trypanosome, which is transmitted by the bite of tsetse flies. First the parasite multiplies in blood and lymph, while evading the human immune system. It then lodges in organs like heart and kidneys and finally in the brain. Patients become disoriented, their sleeping pattern disintegrates and they get motor and mental problems.

23 May 2012

HVTN opens enrollment in GeoVax’s GM-CSF adjuvanted vaccine Phase 1 trial for HIV

GeoVax Labs, Inc., an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced that the NIH-funded HIV Vaccine Trials Network (HVTN) has opened enrollment for a Phase 1 trial for the company's second-generation HIV vaccine.

23 May 2012

Special feature of Science journal highlights protein array technology

A special feature in this week's issue of the journal Science highlights protein array technology, touching on research conducted by Joshua LaBaer, director of the Biodesign Institute's Virginia G. Piper Center for Personalized Diagnostics.

23 May 2012

Inhibition of PBEF could be potential therapeutic target for pulmonary hypertension

Inhibition of pre-B Cell Colony-Enhancing Factor (PBEF) could be a potential therapeutic target for pulmonary hypertension (PH), according to a preclinical study in an animal model of PH.

23 May 2012

Data from Alvine’s ALV003 Phase 2A trial on celiac disease presented at DDW 2012

Alvine Pharmaceuticals, Inc. today announced the presentation of data from a Phase 2A trial of its lead compound, ALV003, at the 2012 Digestive Diseases Week (DDW) meeting held in San Diego, California. The study results met the primary endpoint of demonstrating that oral ALV003, administered in the context of a gluten free diet (GFD), can diminish gluten-induced intestinal mucosal injury in well-controlled celiac disease patients. The company plans to initiate a Phase 2B trial later this year.

23 May 2012

“Sandwich” immunoassay used to search for new chemical reactions

Many discoveries are made by chance, but it is also possible to help it along: The chance of finding something interesting increases when the number of experiments rises. French researchers have now applied this principle to the search for new chemical reactions. In the journal Angewandte Chemie, they have introduced a new concept based on antibodies and a “sandwich” immunoassay.

22 May 2012

Enrollment complete in Xencor, MorphoSys’ MOR208 phase 1 trial for CLL

MorphoSys AG and US-based Xencor, Inc. today announced the successful completion of patient enrollment in the phase 1 clinical trial evaluating MOR208.

22 May 2012

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

New study findings presented today show that subcutaneous induction regimens of the anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis (UC) who had previously failed or were intolerant to conventional agents.

22 May 2012

T cell imbalance may put certain people at increased risk of C. difficile infection

University of Cincinnati (UC) researchers have found that an imbalance in the regulation of certain T cells-the cells in the body that fight off infection or attack the system in certain autoimmune diseases-may put certain people at a higher risk of having recurrent cases of Clostridium difficile, or C. Diff, infection.

22 May 2012

Growth promoting substance in human mesenchymal stem cells spurs restoration of nerves

A substance in human mesenchymal stem cells that promotes growth appears to spur restoration of nerves and their function in rodent models of multiple sclerosis (MS), researchers at Case Western Reserve University School of Medicine have found.

21 May 2012

Biomarker neutralizes effect of bevacizumab in pancreas and kidney cancer patients

Diether Lambrechts (VIB - KU Leuven) said "in two large clinical studies with patients with advanced stages of pancreas and kidney cancer a variant in the DNA was discovered that identified patients who did not respond well to the prescribed course of bevacizumab.

21 May 2012